MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.gastrohep.2022.09.003

Медицинская библиотека · Gastroenterologia y hepatologia · 2022

Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.

Castillo-Regalado Edgar, Ríos Raquel, Aràjol Clàudia, Gely Cristina, Márquez Lucía, Calafat Margalida, González-Muñoza Carlos, Cañete Fiorella, Mesonero Francisco, Guardiola Jordi, Garcia-Planella Esther, Mañosa Míriam, Domènech Eugeni

СтатьяПеревод в очереди

Аннотация

BACKGROUND

In spite of the lack of evidence regarding the clinical benefits of oral 5-aminosalicylic acid (5-ASA) compounds in Crohn's disease (CD), these drugs are frequently used in daily clinical practice, particularly for colonic CD. Our aim is to assess the use and clinical outcomes of 5-ASA of those patients with colonic CD treated with 5-ASA as monotherapy.

METHODS

Patients diagnosed with isolated colonic CD and treated with 5-ASA but never exposed to immunosuppressants or biologicals were identified from the local databases of five referral centres. A retrospective review of clinical and endoscopic outcomes was performed.

RESULTS

Out of 545 patients with isolated colonic CD, 106 (19%) were treated with oral 5-ASA in monotherapy as maintenance therapy. The median follow-up was 144 months (interquartile range [IQR], 48-234). Almost all of the patients (92%) presented an inflammatory pattern and 11% developed perianal disease. Half of the patients had already received 5-ASA at diagnosis, and the median duration of 5-ASA treatment was 107 months (IQR 22.5-187). Endoscopic remission, as defined by the absence of ulcers at the last complete colonoscopy, was observed in 65% of those patients undergoing at least one colonoscopy during follow-up. Male gender and extraintestinal manifestations were associated with a lower likelihood of achieving endoscopic remission. Nine patients required colectomy, but mostly soon after CD diagnosis.

CONCLUSIONS

5-ASA seems to be of benefit in the long-term in one fifth of patients with colonic CD as the only maintenance therapy and should be considered in fragile patients with Crohn's colitis.

Для цитирования: Castillo-Regalado Edgar, Ríos Raquel, Aràjol Clàudia, Gely Cristina, Márquez Lucía, Calafat Margalida, González-Muñoza Carlos, Cañete Fiorella, Mesonero Francisco, Guardiola Jordi, Garcia-Planella Esther, Mañosa Míriam, Domènech Eugeni. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy.. Gastroenterologia y hepatologia. 2022. DOI: 10.1016/j.gastrohep.2022.09.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.